Fcγ receptors as regulators of immune responses
The DOI matches its Crossref record; 138 of the 139 references it cites were found in a registry or an index.
Abstract
In addition to their role in binding antigen, antibodies can regulate immune responses through interacting with Fc receptors (FcRs). In recent years, significant progress has been made in understanding the mechanisms that regulate the activity of IgG antibodies in vivo. In this Review, we discuss recent studies addressing the multifaceted roles of FcRs for IgG (FcgammaRs) in the immune system and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FcγR activation induces macrophage phagocytosis.44”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [44]
Citations
Cites
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo
Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., & Nussenzweig, M. C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.769 · Cited by 1,848
Self-citationShields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754 · cited 1×
“Evidence that this sugar residue is involved in immune regulatory processes was obtained by studying the mechanism of the anti-inflammatory activity of IVIG therap”
BackgroundSelf-citationDifferential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307 · cited 1×
“This sugar side chain consists of a conserved biantennary heptasaccharide core structure containing mannose and N-acetylglucosamine (GlcNac) with varying additions of terminal and branching residues such as fucose, GlcNac, galactose and sialic aci”
BackgroundWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Several studies of lymphoma patients who had received Rituximab, a B-cell depleting chimeric IgG1 antibody that is specific for CD20, revealed that those patients with activating FcγR alleles that had a higher binding affinity for the Fc fragment of the therapeutic antibody displayed significantly improved clinical re…”
Background
Cited by
Items 401–500 of 1,008
Why remission is not enough: underlying disease mechanisms in RA that prevent cure
Schett, G. A., Tanaka, Y., & Isaacs, J. D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00543-5 · Cited by 97
Li, Y., Lee, P. Y., Kellner, E. S., Paulus, M., Switanek, J., Xu, Y., Zhuang, H., Sobel, E. S., Segal, M. S., Satoh, M., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3017 · Cited by 95
“Dysregulated CD64 expression may have functional consequences, as this activating FcγR plays important roles in phagocytosis, cytolysis, and induction of inflammatory cytokines [28].”
BackgroundiRhom2 promotes lupus nephritis through TNF-α and EGFR signaling
Qing, X., Chinenov, Y. V., Redecha, P. B., Madaio, M. P., Roelofs, J. J. T. H., Farber, G., Issuree, P. D. A., Donlin, L. T., Mcllwain, D. R., Mak, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97650 · Cited by 92
The Development of Serum Amyloid P as a Possible Therapeutic
Pilling, D., & Gomer, R. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02328 · Cited by 92
Kasperkiewicz, M., Nimmerjahn, F., Wende, S., Hirose, M., Iwata, H., Jonkman, M. F., Samavedam, U. K. S. R. L., Gupta, Y., Möller, S., Rentz, E., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4023 · Cited by 98
“FcγRs have been described: FcγRI, FcγRIIB, FcγRIII and FcγRIV [30].”
BackgroundInfluentialSelf-citationSingle-Domain Antibodies Targeting Neuraminidase Protect against an H5N1 Influenza Virus Challenge
Cardoso, F. M. L., Ibañez, L. I., den Hoecke, S. V., Baets, S. D., Smet, A., Roose, K., Schepens, B., Descamps, F. J., Fiers, W. C., Muyldermans, S., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03178-13 · Cited by 102
HLA-DQA1 and PLA2R1 Polymorphisms and Risk of Idiopathic Membranous Nephropathy
Bullich, G., Ballarín, J., Oliver, A., Ayasreh, N., Silva, I., Santín, S., Encarnación, M. M. D., Torrá, R., & Ars, E. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05310513 · Cited by 100
Fc gamma receptors: glycobiology and therapeutic prospects
Hayes, J. M., Wormald, M. R., Rudd, P. M., & Davey, G. P. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s121233 · Cited by 103
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
Yu, Y. (2023) · Cancers · doi:10.3390/cancers15082323 · Cited by 107
“Moreover, NK cells can be provoked by antibody opsonization for mediating antibody-dependent cellular cytotoxicity (ADCC) [10].”
BackgroundInfluentialAnti-inflammatory role of the IgA Fc receptor (CD89): From autoimmunity to therapeutic perspectives
Mkaddem, S. B., Rossato, E., Heming, N., & Monteiro, R. C. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.10.011 · Cited by 106
Anumula, K. R. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.05.022 · Cited by 92
The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo
Anthony, R. M., & Nimmerjahn, F. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328342538f · Cited by 93
Self-citationHarnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
“Within the human FcgR family, all but FcgRIIB are immunoreceptor tyrosine-based activation motif (ITAM) bearing activating FcRs that activate upon binding to IgGs via multimerization of intracellular ITAM domains (24, 26).”
BackgroundMuthumani, K., Block, P., Flingai, S., Muruganantham, N., Chaaithanya, I. K., Tingey, C., Wise, M., Reuschel, E. L., Chung, C., Muthumani, A., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw111 · Cited by 89
“Conventional vaccines typically require a lag phase before antibody generation, in addition to multiple immunizations, to be effective [18, 22] .”
BackgroundAntibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors
Kuzmina, N. A., Younan, P. M., Gilchuk, P., Santos, R. I., Flyak, A. I., Ilinykh, P. A., Huang, K., Lubaki, N. M., Ramanathan, P., Crowe, J. E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.035 · Cited by 92
The other side of immunoglobulin G: suppressor of inflammation
Aschermann, S., Lux, A., Baerenwaldt, A., Biburger, M., & Nimmerjahn, F. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.04081.x · Cited by 91
Self-citationMuntasell, A., Cabo, M., Servitja, S., Tusquets, I., Martinez‐García, M., Rovira, A., Rojo, F., Albanell, J., & López‐Botet, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01544 · Cited by 97
Neuroinflammation in dementia with Lewy bodies: a human post-mortem study
Amin, J., Holmes, C., Dorey, R. B., Tommasino, E., Casal, Y. R., Williams, D. M., Dupuy, C., Nicoll, J. A. R., & Boche, D. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00954-8 · Cited by 89
IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses
Aloulou, M., Ben Mkaddem, S., Biarnes-Pelicot, M., Boussetta, T., Souchet, H., Rossato, E., Benhamou, M., Crestani, B., Zhu, Z., Blank, U., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376046 · Cited by 90
A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands
Rodrigues, E., Jung, J., Park, H., Loo, C., Soukhtehzari, S., Kitova, E. N., Mozaneh, F., Daskhan, G. C., Schmidt, E. N., Aghanya, V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18907-6 · Cited by 93
Aoyama, M., Tada, M., Yokoo, H., Demizu, Y., & Ishii‐Watabe, A. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03158-x · Cited by 99
Revenko, A. S., Carnevalli, L. S., Sinclair, C., Johnson, B., Peter, A., Taylor, M. A., Hettrick, L. A., Chapman, M., Klein, S., Solanki, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003892 · Cited by 96
Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells
Haudek, S. B., Trial, J., Xia, Y., Gupta, D., Pilling, D., & Entman, M. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804910105 · Cited by 89
Spontaneous germinal centers and autoimmunity
Domeier, P. P., Schell, S. L., & Rahman, Z. S. M. (2017) · Autoimmunity · doi:10.1080/08916934.2017.1280671 · Cited by 97
Iacob, R. E., Bou-Assaf, G. M., Makowski, L., Engen, J. R., Berkowitz, S. A., & Houde, D. J. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23754 · Cited by 91
Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis
Molfetta, R., Quatrini, L., Santoni, A., & Paolini, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081677 · Cited by 103
“CD16 (FcγRIIIA) is a potent activating receptor expressed on the CD56dimCD16+ NK cell subset that mediates ADCC and cytokine release [93] through the tyrosine phosphorylation of its transducing subunits [94,95].”
BackgroundThe role of CD23 in the regulation of allergic responses
Engeroff, P., & Vogel, M. T. (2021) · Allergy · doi:10.1111/all.14724 · Cited by 94
The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions
Osorio, J. C., Smith, P. T., Knorr, D. A., & Ravetch, J. V. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.007 · Cited by 101
Self-citationStructure of the Murine Unglycosylated IgG1 Fc Fragment
Feige, M. J., Nath, S., Catharino, S., Weinfurtner, D., Steinbacher, S., & Büchner, J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.06.048 · Cited by 89
Pollara, J., Bonsignori, M., Moody, M. A., Pazgier, M., Haynes, B. F., & Ferrari, G. (2013) · Current HIV Research · doi:10.2174/1570162x113116660059 · Cited by 96
Development and characterization of an anti-rituximab monoclonal antibody panel
Tada, M., Suzuki, T., & Ishii‐Watabe, A. (2018) · mAbs · doi:10.1080/19420862.2018.1424610 · Cited by 88
Li, J., Ye, Y., Liu, Z., Zhang, G., Dai, H., Li, J., Zhou, B., Li, Y., Zhao, Q., Huang, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00354-5 · Cited by 90
Buhre, J. S., Pongrácz, T., Künsting, I., Lixenfeld, A. S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H. B., Dühring, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020844 · Cited by 103
“Agalactosylated (G0) IgG Abs have been linked to severe conditions in inflammatory (auto-) immune diseases, whereas IgG sialylation has been associated with a decreased affinity of IgG to classical activating FcyRs and lower or anti-inflammatory effects (21, 24, 36, 37, 44–52).”
BackgroundXiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症:英文版 · doi:10.1002/cac2.12579 · Cited by 96
“…intrinsic function of Fc γ R-IIB in inhibiting mouse and human CD8 + T-cell responses, regulated by fibrinogen-like protein 2 (Fgl2) as a functional ligand, which modulates the apoptotic signaling pathway of CD8 + T cells, challenging the previous notion that “T cells do not express FcRs” [186].”
BackgroundInfluentialHER2-family signalling mechanisms, clinical implications and targeting in breast cancer
Elster, N., Collins, D. M., Toomey, S., Crown, J. P., Eustace, A. J., & Hennessy, B. T. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3250-x · Cited by 97
“The interaction of mAb therapies with Fcreceptors expressed on effector immune cells is the basis of ADCC, [43] and the association between tumour-infiltrating lymphocytes and benefit from trastuzumab and chemotherapy has been observed in The FinHER and GeparQuattro trials [44, 45].”
BackgroundCross-Talk between TLR4 and FcγReceptorIII (CD16) Pathways
Rittirsch, D., Flierl, M. A., Day, D. E., Nadeau, B. A., Zetoune, F. S., Sarma, J. V., Werner, C. M. L., Wanner, G. A., Simmen, H., Huber-Lang, M. S., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000464 · Cited by 87
“The cellular response is determined by the balance between activating (ITAM, immunoreceptor tyrosine-based activation motif) and inhibitory (ITIM, immunoreceptor tyrosine-based inhibitory motif) signals [10,11,12,13].”
BackgroundPeruzzi, G., Femnou, L. K., Gil-Krzewska, A. J., Borrego, F., Weck, J., Krzewski, K., & Coligan, J. E. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300313 · Cited by 93
Structural analysis of Fc/FcγR complexes: a blueprint for antibody design
Caaveiro, J. M. M., Kiyoshi, M., & Tsumoto, K. (2015) · Immunological Reviews · doi:10.1111/imr.12365 · Cited by 103
Delidakis, G., Kim, J. E., George, K., & Georgiou, G. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082721-024500 · Cited by 87
Aung, T. N., Monkman, J. H., Warrell, J., Vathiotis, I. A., Bates, K., Gavrielatou, N., Trontzas, I. P., Tan, C. W., Fernandez, A. I., Moutafi, M. K., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02351-7 · Cited by 116
β 2 integrins inhibit TLR responses by regulating NF ‐κ B pathway and p38 MAPK activation
Yee, N. K., & Hamerman, J. A. (2013) · European Journal of Immunology · doi:10.1002/eji.201242550 · Cited by 98
Human Fc Receptor–Like 5 Binds Intact IgG via Mechanisms Distinct from Those of Fc Receptors
Franco, A., Damdinsuren, B., Ise, T., Dement-Brown, J., Li, H., Nagata, S., & Tolnay, M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202860 · Cited by 85
“The discovery that FCRL5 is a specific IgG receptor suggests a role for secreted IgG regulating B cells through FCRL5, analogous to FcgRIIB (23).”
BackgroundPolymeric human Fc-fusion proteins with modified effector functions
Mekhaiel, D. N. A., Czajkowsky, D. M., Andersen, J. T., Shi, J., El-Faham, M., Doenhoff, M., McIntosh, R. S., Sandlie, I., He, J., Hu, J., et al. (2011) · Scientific Reports · doi:10.1038/srep00124 · Cited by 85
“Similarly, the Fc region of Abs is increasingly being explored as an Ag delivery vehicle in adjuvants for the induction of protective immunity or tolerance owing to their ability to activate specific FcgRs that trigger activating and/or inhibitory signalling pathways that set thresholds for well-balanced immune respon…”
BackgroundSweet but dangerous – the role of immunoglobulin G glycosylation in autoimmunity and inflammation
Biermann, M. H. C., Griffante, G., Podolska, M. J., Boeltz, S., Stürmer, J., Munoz, L. E., Bilyy, R. O., & i, M. H. (2016) · Lupus · doi:10.1177/0961203316640368 · Cited by 97
IL-33–dependent induction of allergic lung inflammation by FcγRIII signaling
Tjota, M. Y., Williams, J. W., Lu, T., Clay, B. S., Byrd, T. T., Hrusch, C. L., Decker, D. C., de Araujo, C. A., Bryce, P. J., & Sperling, A. I. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63802 · Cited by 90
Pentraxins and Fc Receptor-Mediated Immune Responses
Lu, J., Mold, C., Clos, T. W. D., & Sun, P. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02607 · Cited by 88
Receptor mobility, the cytoskeleton, and particle binding during phagocytosis
Jaumouillé, V., & Grinstein, S. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.10.006 · Cited by 106
Thon, J. N., Devine, M. T., Begonja, A. J., Tibbitts, J., & Italiano, J. E. (2012) · Blood · doi:10.1182/blood-2012-04-420968 · Cited by 86
FcRn: From Molecular Interactions to Regulation of IgG Pharmacokinetics and Functions
Challa, D. K., Velmurugan, R., Ober, R. J., & Ward, E. S. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_12 · Cited by 104
Williams, K. L., Wahala, W. M. P. B., Orozco, S. L., de Silva, A. M., & Harris, E. (2012) · Virology · doi:10.1016/j.virol.2012.03.003 · Cited by 83
“While the interactions between human IgG and mouse Fcγ receptor (FcγR) are not identical in either specificity or strength of binding (Nimmerjahn and Ravetch, 2008), human IgG has been shown to bind to relevant mouse FcγRs (Ravetch and Anderson, 1990).”
BackgroundImpact of Differential Glycosylation on IgG Activity
Lux, A., & Nimmerjahn, F. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-5632-3_10 · Cited by 91
Self-citationSchulze, F. S., Beckmann, T., Nimmerjahn, F., Ishiko, A., Collin, M., Köhl, J., Goletz, S., Zillikens, D., Ludwig, R. J., & Schmidt, E. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.05.007 · Cited by 83
Self-citationInfluenza and Antibody-Dependent Cellular Cytotoxicity
Holle, T. A. V., & Moody, M. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01457 · Cited by 90
NK Cell Therapy: A Rising Star in Cancer Treatment
Du, N., Guo, F., Wang, Y., & Cui, J. (2021) · Cancers · doi:10.3390/cancers13164129 · Cited by 87
Dugast, A., Tonelli, A., Berger, C. T., Ackerman, M. E., Sciaranghella, G., Liu, Q., Sips, M., Tóth, I., Trocha, A. K., Ghebremichael, M. S., et al. (2011) · Virology · doi:10.1016/j.virol.2011.03.012 · Cited by 87
“…including monocytes/macrophages, granulocytes, DC, and mast cells that express both inhibitory and activating FcγR, natural killer (NK) cells that express the activating receptor FcγRIIIa, and B cells that only express the inhibitory receptor FcγRIIb (Anderson, 1989; Nimmerjahn and Ravetch, 2008).”
BackgroundInfluentialMendoza-Coronel, E., & Ortega, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00303 · Cited by 82
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
Foley, B. A., Felices, M., Cichocki, F. M., Cooley, S., Verneris, M. R., & Miller, J. S. (2014) · Immunological Reviews · doi:10.1111/imr.12157 · Cited by 92
den Dunnen, J., Vogelpoel, L. T. C., Wypych, T. P., Muller, F. J. M., de Boer, L., Kuijpers, T. W., Zaat, S. A. J., Kapsenberg, M. L., & de Jong, E. C. (2012) · Blood · doi:10.1182/blood-2011-12-399931 · Cited by 98
Tsang-A-Sjoe, M. W. P., Nagelkerke, S. Q., Bultink, I. E. M., Geissler, J., Tanck, M. W. T., Tacke, C. E. A., Ellis, J. A., Zenz, W., Bijl, M., Berden, J. H. M., et al. (2016) · Rheumatology · doi:10.1093/rheumatology/kev433 · Cited by 83
Glowalla, E., Tosetti, B., Krönke, M., & Krut, O. (2009) · Infection and Immunity · doi:10.1128/iai.00617-08 · Cited by 94
Ji, T., Lang, J., Ning, B., Qi, F., Wang, H., Zhang, Y., Zhao, R., Yang, X. P., Zhang, L., Li, W., et al. (2018) · Advanced Materials · doi:10.1002/adma.201804395 · Cited by 81
Pander, J., Gelderblom, H. A. J., Antonini, N. F., Tol, J., van Krieken, J. H., van der Straaten, T., Punt, C. J. A., & Guchelaar, H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.017 · Cited by 88
A signal-switch hypothesis for cross-regulation of cytokine and TLR signalling pathways
Ivashkiv, L. B. (2008) · Nature Reviews Immunology · doi:10.1038/nri2396 · Cited by 80
Reiling, L., Richards, J. S., Fowkes, F. J. I., Wilson, D. W., Chokejindachai, W., Barry, A. E., Tham, W., Stubbs, J., Langer, C., Donelson, J. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045253 · Cited by 80
Schurich, A., Böttcher, J. P., Burgdorf, S., Penzler, P., Hegenbarth, S., Kern, M., Dolf, A., Endl, E., Schultze, J., Wiertz, E., et al. (2009) · Hepatology · doi:10.1002/hep.23075 · Cited by 82
B cells and their mediators as targets for therapy in solid tumors
Gunderson, A. J., & Coussens, L. M. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.03.005 · Cited by 80
Hmiel, L. K., Brorson, K., & Boyne, M. T. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8108-x · Cited by 92
“Higher levels of bisecting GlcNAc correlate with both increased FcγRIIIa binding [50, 90] and ADCC activity [38, 49], although these effects are largely due to the high levels of afucosylation associated with most bisected glycoforms.”
BackgroundInfluentialBurkard, M., Leischner, C., Lauer, U. M., Busch, C., Venturelli, S., & Frank, J. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.01.006 · Cited by 83
de Aguiar, R. B., & de Moraes, J. Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01023 · Cited by 88
Li, Q., Qian, C., Chen, Y., Bai, Y., Bao, Y., Lu, L., & Cao, X. (2012) · Blood · doi:10.1182/blood-2011-08-377242 · Cited by 91
Snyder, K. M., Hullsiek, R., Mishra, H. K., Mendez, D. C., Li, Y., Rogich, A., Kaufman, D. S., Wu, J., & Walcheck, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02873 · Cited by 81
Romberg, N. D., Coz, C. L., Glauzy, S., Schickel, J., Trofa, M., Nolan, B. E., Paessler, M. E., Xu, M. L., Lambert, M. P., Lakhani, S. A., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.06.012 · Cited by 78
Human FcγRII Cytoplasmic Domains Differentially Influence Antibody-Mediated Dengue Virus Infection
Boonnak, K., Slike, B. M., Donofrio, G. C., & Marovich, M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203052 · Cited by 78
Autoimmunity and autoinflammation: A systems view on signaling pathway dysregulation profiles
Arakelyan, A., Nersisyan, L., Poghosyan, D., Khondkaryan, L., Hakobyan, A., Loeffler‐Wirth, H., Melanitou, E., & Binder, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187572 · Cited by 95
Andersson, C. R., Falsig, J., Stavenhagen, J. B., Christensen, S., Kartberg, F., Rosenqvist, N., Finsen, B., & Pedersen, J. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-41105-4 · Cited by 76
Antibody modulation of B cell responses—Incorporating positive and negative feedback
Cyster, J. G., & Wilson, P. C. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.009 · Cited by 84
Perez, L. G., Costa, M. R., Todd, C. A., Haynes, B. F., & Montefiori, D. C. (2009) · Journal of Virology · doi:10.1128/jvi.00656-09 · Cited by 88
“Indeed, it has been suggested that these receptors on DC play a role in regulating antigen uptake, antigen presentation, and cell activation (68, 82).”
BackgroundInfluentialQu, L., Zhang, P., LaMotte, R. H., & Ma, C. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.04.008 · Cited by 77
“Fax: +1 203 and inhibitory receptors (Nimmerjahn and Ravetch, 2006, 2008).”
BackgroundInfluentialCheng, Z.-J. J., Garvin, D., Paguio, A., Moravec, R. A., Engel, L., Fan, F., & Surowy, T. K. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.07.010 · Cited by 83
Low-affinity Fcγ receptors, autoimmunity and infection
Willcocks, L. C., Smith, K. G. C., & Clatworthy, M. R. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001161 · Cited by 81
Persistent Lung Inflammation and Fibrosis in Serum Amyloid P Component (Apcs-/-) Knockout Mice
Pilling, D., & Gomer, R. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093730 · Cited by 74
DC subset–specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo
Lehmann, C. H. K., Baranska, A., Heidkamp, G. F., Heger, L., Neubert, K., Lühr, J. J., Hoffmann, A., Reimer, K. C., Brückner, C., Beck, S., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160951 · Cited by 79
“…FcγRs set a threshold for DC activation, thereby modulating the strength of the resulting T cell response to antigens within immune complexes (den Haan and Bevan, 2002; Kalergis and Ravetch, 2002; Steinman et al., 2003a; Boruchov et al., 2005; Dhodapkar et al., 2005; Nimmerjahn and Ravetch, 2008).”
BackgroundSelf-citationReview of immune tolerance induction in hemophilia A
Schep, S. J., Schutgens, R. E. G., Fischer, K., & Boes, M. L. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.003 · Cited by 89
Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 88
The clinical significance of allergen-specific IgG4 in allergic diseases
Qin, L., Tang, L.-F., Cheng, L., & Wang, H.-Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032909 · Cited by 71
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 94
“…3A(1–3)): At the first stage, effector cell recruitment: Fc-receptor-bearing immune cells, like natural killer (NK) cells, macrophages, and neutrophils, are drawn to the tumor site via interactions between their Fc receptors and the Fc segment of the antibody bound to the malignant cell [86,87].”
BackgroundTrotta, A. M., Ottaiano, A., Romano, C., Nasti, G., Nappi, A. G., Divitiis, C. D., Napolitano, M., Zanotta, S., Casaretti, R., D’Alterio, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0184 · Cited by 86
Dual transcriptomic and epigenomic study of reaction severity in peanut-allergic children
Do, A. N., Watson, C. T., Cohain, A. T., Griffin, R. S., Grishin, A. V., Wood, R. A., Burks, A. W., Jones, S. M., Scurlock, A. M., Leung, D. Y. M., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.10.040 · Cited by 78
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 82
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Schlam, I. M., Tarantino, P., & Tolaney, S. M. (2022) · Cancers · doi:10.3390/cancers14163996 · Cited by 88
“Margetuximab was engineered to retain the epitope specificity of trastuzumab; however, five amino acids were modified to increase affinity for the activating Fcγ receptor CD16A and to decrease activity to the inhibitory Fcγ receptor CD32B, with the goal to enhance ADCC [17,18].”
BackgroundYofe, I., Landsberger, T., Yalin, A., Solomon, I., Costoya, C., Demane, D. F., Shah, M., David, E., Borenstein, C., Barboy, O., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00447-1 · Cited by 83
“5 10 .0 Ctla4 expression Scaled expression 78 3 4 6 5 20 19 10 13 11 12 18 21 15 14 17 16 22 2 1 9 78 3 4 6 5 20 19 10 13 11 12 18 21 15 14 17 16 22 2 1 9 Lymphoid cells Myeloid cells NK Ncr1 (1) CD8 Xcl1 (2) CD8 Pdcd1 (3) CD8 Ccl4 (4) CD8 Ccl5 (5) CD8 Lef1 (6) CD4 Cxcr6 (7) CD4 Ifit1 (8) Treg Foxp3 (9) TAM Arg1 (10)…”
InfluentialLiu, Z., Gunasekaran, K., Wang, W., Razinkov, V. I., Sekirov, L., Leng, E. C., Sweet, H., Foltz, I. N., Howard, M., Rousseau, A.-M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513366 · Cited by 83
“Engagement of activating Fc Rs can lead to a variety of antibody effector functions (2, 3) such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP).”
BackgroundPrimer on tumor immunology and cancer immunotherapy
Harris, T. J., & Drake, C. G. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-12 · Cited by 86
“be activating or inhibitory [10].”
Multiplexed Analytical Glycomics: Rapid and Confident IgG N-Glycan Structural Elucidation
Mittermayr, S., Bones, J., Doherty, M., Guttman, A., & Rudd, P. M. (2011) · Journal of Proteome Research · doi:10.1021/pr200371s · Cited by 75
Yang, D., Kroe‐Barrett, R., Singh, S., Roberts, C. J., & Laue, T. M. (2017) · mAbs · doi:10.1080/19420862.2017.1367074 · Cited by 78
“Three different classes of human FcgRs have been identified: FcgRI (CD64), FcgRII (CD32) with A, B, and C isoforms, and FcgRIII (CD16) with 2 isoforms.(9) Monomeric IgG binds to each FcgR with affinity ranges from 10(8) M¡1 for FcgRI to 10(4)– 10(7) M¡1 for FcgRII and FcgRIII.”
BackgroundAutoimmune regulation of chronic pain
Lacagnina, M. J., Heijnen, C. J., Watkins, L. R., & Grace, P. M. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000905 · Cited by 82
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Zhang, D., He, G., & Meng, F. (2021) · Molecules · doi:10.3390/molecules26164907 · Cited by 79
“Most FcγRs can only interact with antibodies in the form of immune complexes (IC), leading to highavidity binding [41].”
BackgroundCOVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
Furlan, A., Forner, G., Cipriani, L., Vian, E., Rigoli, R., Gherlinzoni, F., & Scotton, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763412 · Cited by 78
“Time for oxygen weaning after resolutive therapy, median (range), days 5 (1-45) NR NR”
BackgroundReview of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Ran, F., Liu, Y., Wang, C., Xu, Z., Zhang, Y., Liu, Y., Zhao, G., & Ling, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114009 · Cited by 79
Metadata
- Authors
- Nimmerjahn, F., & Ravetch, J. V.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Rockefeller University (US)
- Venue
- Nature Reviews Immunology
- Published
- 2008-01
- Volume
- 8
- Issue
- 1
- Pages
- 34-47
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2075901113
- Cited by
- 2,947
- References
- 139
- Citations by year
- 2026: 186 · 2025: 176 · 2024: 158 · 2023: 174 · 2022: 169 · 2021: 196 · 2020: 158 · 2019: 188 · 2018: 151 · 2017: 161 · 2016: 158 · 2015: 170 · 2014: 165 · 2013: 162 · 2012: 181
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- Fc gamma receptor, IgG, antibody subclasses, immune regulation, therapeutic antibodies, autoimmune disease, infectious diseases, cancer immunotherapy, antibody effector functions
- MeSH terms
- Animals, Humans, Immunoglobulin G, Immunity, Receptors, Fc
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.